Scandinavian ChemoTech AB Class B

Scandinavian ChemoTech AB Class B's next confirmed earnings release is scheduled for August 11, 2026.

As of March 31, 2026, Scandinavian ChemoTech AB Class B has 25.45M shares outstanding.

As of March 31, 2026, Scandinavian ChemoTech AB Class B maintains a current ratio of 0.79, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended March 31, 2026, Scandinavian ChemoTech AB Class B posted a negative return on equity (ROE) of -236.48, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -52.18, reflecting losses generated across the asset base. The company generates approximately 12.61M in revenue per employee across its workforce of 1.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.48 indicates how many times Scandinavian ChemoTech AB Class B sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Scandinavian ChemoTech AB Class B generated 12.61M in revenue and converted that into -6.31M in net income, yielding earnings per share of -0.26. EBITDA reached -3.29M, while operating income came in at -5.27M.

These figures are as of March 31, 2026. Total book value stands at 1.64M, with working capital of -1.99M providing operational flexibility.

Scandinavian ChemoTech AB Class B produced -3.65M in operating cash flow over the twelve months ended March 31, 2026.

Over the twelve months ended March 31, 2026, Scandinavian ChemoTech AB Class B posted a gross margin of 87.44, reflecting its pricing power and cost economics. The operating margin of -41.83 and net profit margin of -50.01 provide insight into operational efficiency.

Scandinavian ChemoTech AB Class B's most recent stock split took place on May 30, 2024.